Resilience and Lilly commit $750 million to expand US-manufactured medicine supply

Eli Lilly and the contract manufacturer Resilience announced on August 19, 2026, that they are expanding a manufacturing partnership with $750 million in combined investment aimed at increasing the volume of medicines made in the United States ^[1]. The expansion builds on a relationship the two companies first set up in 2023 ^[1].

The new money will grow Resilience's operations in the Cincinnati, Ohio region to include production of Lilly's KwikPen, the injectable device used for the company's diabetes and obesity treatments ^[1]. Lilly makes tirzepatide, sold as Mounjaro for diabetes and Zepbound for weight loss, in prefilled pen and vial forms. The companies did not say how much of the new capacity will go specifically toward incretin products such as tirzepatide, according to the announcement.

The expansion is expected to create at least 400 new jobs, which would bring the total number of Ohio jobs tied to the Resilience-Lilly partnership to more than 1,400 ^[1]. Site preparation is already underway, with full operations expected to start in early 2027 ^[1]. Resilience currently runs two facilities in the Cincinnati area totaling nearly 1 million square feet and employing close to 1,000 workers across manufacturing, quality, and regulatory functions ^[1]. The company also recently moved its global headquarters to Blue Ash, Ohio ^[1].

According to the companies, the partnership has already produced more than 150 million doses of medicines for U.S. patients in vial and prefilled syringe formats since it began ^[1][2]. Lilly executive Edgardo Hernandez said that as demand for the company's medicines keeps rising, scaling up complex manufacturing requires "proven technical capability" and the ability to "deliver consistently over time" ^[1]. Resilience CEO William Marth said the investment reflects a long-term commitment to building one of the largest sterile injectable and device assembly operations in the country ^[1]. Ohio Governor Mike DeWine and JobsOhio President J.P. Nauseef also welcomed the expansion as validation of the state's biomanufacturing workforce and infrastructure ^[1].

One secondary source describes the underlying arrangement as a "10-year biomanufacturing partnership" covering process development, drug substance, and drug product manufacturing, a detail not confirmed in the primary announcement, which refers only to a "multi-year" partnership ^[1][2]. That source also references an unrelated $225 million allocation mentioned by a third party, adding to the uncertainty about exact investment figures tied to this specific expansion ^[2]. Readers should treat those particular details as unconfirmed.

Why it matters for patients

For patients using or waiting for GLP-1 medicines like Mounjaro and Zepbound, more domestic manufacturing capacity for injector pens could eventually support supply as demand for these drugs remains high. But the companies did not specify how much of this new capacity is dedicated to incretin products versus other medicines Lilly makes, so it is not yet known whether this expansion will directly ease shortages or waitlists tied to tirzepatide products ^[1]. The new capacity also will not come online immediately: full operations are not expected until early 2027 ^[1], so any effect on supply availability would not be immediate.

The announcement is about manufacturing capacity and jobs, not about pricing, insurance coverage, or approval of new products. It does not change anything about who qualifies for these medicines or how they are prescribed.

What happens next

Site preparation at the Ohio facilities is underway now, with the companies targeting early 2027 for full operations at the expanded campus ^[1]. No further milestones or capacity breakdowns specific to GLP-1 products have been disclosed in the sources reviewed.